View Older Stories View More Recent Stories

Oct 28, 2024 08:00AM AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
Oct 24, 2024 11:32AM AbbVie (ABBV) and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions
Oct 24, 2024 11:30AM AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions
Oct 18, 2024 07:44PM BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
Oct 17, 2024 08:03AM AbbVie (ABBV): U.S. FDA Approves VYALEV for Adults Living with Advanced Parkinson's Disease
Oct 17, 2024 08:00AM U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease
Oct 16, 2024 08:00AM Allergan Aesthetics to Present New Data at 2024 American Society for Dermatologic Surgery (ASDS) to Showcase Depth Across Facial Aesthetics and Insight into Patient Perception
Oct 4, 2024 09:00AM Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM
Oct 2, 2024 08:00AM Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
Oct 1, 2024 08:00AM AbbVie to Host Third-Quarter 2024 Earnings Conference Call
Sep 27, 2024 12:17PM AbbVie (ABBV) Submits Biologics License Application to the FDA for Telisotuzumab Vedotin
Sep 27, 2024 12:13PM AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
Sep 26, 2024 08:00AM AbbVie (ABBV) Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Sep 26, 2024 08:00AM AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Sep 25, 2024 07:01AM AbbVie (ABBV): New Analysis Demonstrates the Efficacy of RINVOQ in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
Sep 25, 2024 07:00AM New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
Sep 24, 2024 08:00AM Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns
Sep 20, 2024 07:33AM AbbVie (ABBV) Receives Positive CHMP Opinion for Mirvetuximab Soravtansine for the Treatment of Certain Adult Ovarian Cancer
Sep 20, 2024 07:32AM AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer
Sep 11, 2024 08:31AM AbbVie's (ABBV) Allergan Aesthetics Launches BOTOX Cosmetic for Masseter Muscle Prominence in Adults in China
Sep 11, 2024 08:30AM Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China
Sep 9, 2024 09:00AM AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
Sep 6, 2024 10:13AM AbbVie Declares Quarterly Dividend
Sep 4, 2024 09:15AM New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
Aug 27, 2024 08:15AM AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
Aug 27, 2024 08:07AM AbbVie (ABBV): SkinMedica Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator
Aug 27, 2024 08:05AM SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator
Aug 19, 2024 02:06PM AbbVie (ABBV): EC Grants Second Indication Approval for TEPKINLY for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Aug 19, 2024 02:05PM European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Aug 1, 2024 08:24AM AbbVie (ABBV) Completes Acquisition of Cerevel Therapeutics
Aug 1, 2024 08:23AM AbbVie Completes Acquisition of Cerevel Therapeutics
Jul 30, 2024 08:00AM Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day
Jul 26, 2024 06:39AM AbbVie (ABBV) Announces European Commission Approval of SKYRIZI for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Jul 26, 2024 02:00AM AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Jul 25, 2024 08:30AM Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
Jul 25, 2024 07:36AM AbbVie Reports Second-Quarter 2024 Financial Results
Jul 12, 2024 08:31AM AbbVie (ABBV) Submits Regulatory Applications to FDA and EMA for Upadacitinib in Giant Cell Arteritis
Jul 12, 2024 08:30AM AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis
Jul 10, 2024 08:00AM AbbVie (ABBV) Appoints Roopal Thakkar as and Chief Scientific Officer
Jul 10, 2024 08:00AM AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer
Jul 2, 2024 08:00AM AbbVie to Host Second-Quarter 2024 Earnings Conference Call
Jul 1, 2024 08:00AM AbbVie (ABBV) Appoints Robert A. Michael as CEO
Jul 1, 2024 08:00AM Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
Jun 28, 2024 02:00AM AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Jun 27, 2024 09:27AM AbbVie (ABBV) Acquires Celsius Therapeutics for $250 Million
Jun 27, 2024 09:26AM AbbVie Acquires Celsius Therapeutics
Jun 27, 2024 08:33AM AbbVie (ABBV) Introduces Alle Payment Plans
Jun 27, 2024 08:30AM Introducing Allē Payment Plans, Powered by Cherry
Jun 27, 2024 05:44AM AbbVie (ABBV) Announces Second FDA Approval for EPKINLY
Jun 26, 2024 07:03PM U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
View More Recent Stories View Older Stories